Compare GSK plc (GSK) vs Sezzle Inc (SEZL) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Sezzle (SEZL) trades at $188.03, up 3.09% today and showing strong bullish momentum with the current price near its pivot point of $187. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.43 exceeding the $1.24 forecast. Technical indicators show a bullish trend with moving averages supporting upward movement, while fundamentals reveal impressive profitability with 71.36% gross margins and 91.95% ROE.

The outlook remains positive with raised 2026 guidance and expanding product offerings, though valuation multiples appear elevated with a P/E of 45. Key risks include potential securities law investigations and competitive pressures in the BNPL sector. Analyst sentiment is split evenly between Buy and Hold ratings with a $162 consensus target, suggesting cautious optimism amid strong operational performance.